Complete financial analysis of AVROBIO, Inc. (AVRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AVROBIO, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Games Global Limited (GGL) Income Statement Analysis – Financial Results
- Exotic Food Public Company Limited (XO.BK) Income Statement Analysis – Financial Results
- Publichnoe Akcionernoe Obshestvo “Kostromskaya Sbytovaya Compania” (KTSB.ME) Income Statement Analysis – Financial Results
- STORE Capital Corporation (0LA6.L) Income Statement Analysis – Financial Results
- Israel Opportunity – Energy Resources, LP (ISOP.TA) Income Statement Analysis – Financial Results
AVROBIO, Inc. (AVRO)
About AVROBIO, Inc.
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 617.00K | 4.17M | 1.40M | 1.21M | 850.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -617.00K | -4.17M | -1.40M | -1.21M | -850.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 47.08M | 72.19M | 83.11M | 87.24M | 54.97M | 35.10M | 15.19M | 2.66M |
| General & Administrative | 22.69M | 33.25M | 35.73M | 32.99M | 20.84M | 11.15M | 3.20M | 1.96M |
| Selling & Marketing | 23.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.97M | 33.25M | 35.73M | 32.99M | 20.84M | 11.15M | 3.20M | 1.96M |
| Other Expenses | 0.00 | -456.00K | -285.00K | 516.00K | 2.84M | -118.00K | -19.00K | -6.00K |
| Operating Expenses | 71.05M | 105.43M | 118.84M | 120.23M | 75.81M | 46.24M | 18.39M | 4.63M |
| Cost & Expenses | 71.67M | 105.43M | 118.84M | 120.23M | 75.81M | 46.24M | 18.39M | 4.63M |
| Interest Income | 2.42M | 299.00 | 0.00 | 719.00K | 2.93M | 1.73M | 57.00K | 6.00K |
| Interest Expense | 2.42M | 299.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 617.00K | 1.44M | 1.40M | 1.21M | 850.00K | 380.00K | 45.00K | 39.00K |
| EBITDA | -71.05M | -105.43M | -118.84M | -120.23M | -75.81M | -46.24M | -18.04M | -4.59M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -71.67M | -105.43M | -118.84M | -120.23M | -75.81M | -46.24M | -18.39M | -4.63M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.34M | -456.00K | -285.00K | 516.00K | 2.84M | -118.00K | -262.00K | -39.00K |
| Income Before Tax | 12.53M | -105.89M | -119.13M | -119.71M | -72.97M | -46.36M | -18.65M | -4.66M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 377.00K | 157.00K | -1.40M | -1.21M | -850.00K | -118.00K | 243.00K | -6.00K |
| Net Income | 12.16M | -106.05M | -117.73M | -118.51M | -72.12M | -46.36M | -18.65M | -4.66M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.27 | -2.42 | -2.75 | -3.27 | -2.63 | -3.45 | -1.15 | -0.67 |
| EPS Diluted | 0.27 | -2.42 | -2.75 | -3.27 | -2.63 | -3.45 | -1.15 | -0.67 |
| Weighted Avg Shares Out | 44.33M | 43.74M | 42.85M | 36.21M | 27.43M | 13.44M | 16.19M | 6.92M |
| Weighted Avg Shares Out (Dil) | 44.57M | 43.74M | 42.85M | 36.21M | 27.43M | 13.44M | 16.19M | 6.92M |
Avrobio: Net-Net Biotech Pursuing Strategic Alternatives
After monetizing one of its pipeline candidates, Avrobio has cash well in excess of its market cap. The company announced its search for strategic alternatives recently. The process could close its valuation gap soon. There is potential for significantly more...
AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%
AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday.
AVROBIO to Explore Strategic Alternatives
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it has completed a review of its business, including the status of its programs,...
How to Handle Penny Stocks Volatility in 2023
Penny stocks continue to offer incredible opportunities for investors in 2023. As high-growth, micro-cap equities, they have the potential to outperform traditional stocks, particularly given their inherent affordability, which allows for a broader, more diversified portfolio.
Why Is AVROBIO (AVRO) Stock Up 83% Today?
AVROBIO (NASDAQ: AVRO ) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NYSE: NVS ). This deal has Novartis agreeing to pay $87.5 million in cash to AVROBIO for an...
AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study
Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different tissues.
AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study
AVROBIO Inc (NASDAQ: AVRO) reported new interim data from the Phase 1/2 gene therapy trial of AVR-RD-04 for cystinosis. Cystinosis is a condition characterized by the accumulation of the amino acid cystine (a building block of proteins) within cells.
After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data
Avrobio Inc's AVRO gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year after infusion. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
Trading Penny Stocks? Top Stock Market News for February 9th, 2022
What you need to know about trading penny stocks today The post Trading Penny Stocks? Top Stock Market News for February 9th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 19.7% in 4 Weeks
The heavy selling pressure might have exhausted for AVROBIO, Inc. (AVRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock...
Source: https://incomestatements.info
Category: Stock Reports